drugsTreatmentPhase 3

Varegacestat

Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.

Varegacestat (AL102) is a small-molecule drug developed by Immunome. The sponsor describes its target as gamma secretase / Notch signalling, which OnCo does not yet have a target page for. The sponsor states: AL102 (varegacestat) is a small-molecule inhibitor of gamma secretase-mediated Notch signalling. ClinicalTrials.gov describes the intervention as: AL102 is an inhibitor of gamma secretase-mediated Notch signaling. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04871282 (A Study of AL102 in Patients With Progressing Desmoid Tumours), in desmoid tumour. The largest, NCT04871282, plans to enrol 198 participants (actual) with primary completion expected 2025-12-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

What is being done about this

Resistance to treatment

and how the field plans to fix it →

Available now

AmivantamabApproved
CamizestrantApproved
Comprehensive genomic profilingStandard of care
Liquid biopsy (ctDNA)Standard of care
LorlatinibApproved
MRD / molecular residual disease testingEstablished

In trials

ADC payload neutralisersPhase 1
BGB-16673Phase 3
Bispecific ADCPhase 3
BRUIN CLL-321Positive
CaDAnCe-304Recruiting
CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active

Ideas and roadmaps

Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.

Modality

small molecule

Mechanism

AL102 (varegacestat) is a small-molecule inhibitor of gamma secretase-mediated Notch signalling.

Brand / code

AL102

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Varegacestat

intervention: Varegacestat

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.